88899-85-8

Basic information

• Product Name: (2E)-3-[4-(Methylsulfonyl)phenyl]propenoic acid
• Synonyms: 3-(4-(methylsulfonyl)phenyl)acrylic acid
• CAS NO: 88899-85-8
• Molecular Formula: C₁₀H₁₀O₄S
• Molecular Weight: 226
• Mol File: 88899-85-8.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2E)-3-[4-(Methylsulfonyl)phenyl]propenoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2E)-3-[4-(Methylsulfonyl)phenyl]propenoic acid(88899-85-8)
• EPA Substance Registry System: (2E)-3-[4-(Methylsulfonyl)phenyl]propenoic acid(88899-85-8)

Safety Data

• Hazardous Substances Data: 88899-85-8(Hazardous Substances Data)

Usage

General Description

(2E)-3-[4-(Methylsulfonyl)phenyl]propenoic acid, also known as mesulfen or mesulfone, is a chemical compound with the molecular formula C10H10O4S. It is a derivative of acrylic acid and contains a phenyl ring with a methylsulfonyl group attached to it. Mesulfen has been used as a treatment for certain skin conditions, such as acne and rosacea, due to its anti-inflammatory and antibacterial properties. Additionally, it has shown potential as a therapeutic agent for autoimmune diseases and organ transplant rejection. Mesulfen is also being investigated for its potential use as a chemical intermediate in the synthesis of other pharmaceuticals and agrochemicals. However, due to its potential for skin irritation and allergic reactions, mesulfen should be handled and used with caution.

Upstream product

• 100515-19-3 1-(1,1-dimethoxy-methyl)-4-methanesulfonyl-benzene 
• 100515-17-1 1-(1,1-dimethoxy-methyl)-4-methylsulfanyl-benzene 
• 5398-77-6 para-methanesulfonylbenzaldehyde 
• 3466-32-8 4-bromoohenyl methyl sulfone 
• 7681-38-1 sodium hydrogen sulfate 
• 137473-27-9 ethyl (2E)-3-[4-(methylsulfonyl)phenyl]acrylate 
• 3446-89-7 4-(Methylthio)benzaldehyde 
• 710-24-7 4-acetamidobenzenesulfinic acid 
• 22821-76-7 4-(methylsulfonyl)benzonitrile 
• 5470-49-5 4-methanesulfonylphenylamine 
• 22821-80-3 N-(4-methanesulfonylphenyl)acetamide 
• 125872-45-9 ethyl (E)-3-<4-(methylthio)phenyl>propenoate 
• 1879-16-9 1-methoxy-4-methylsulfanyl-benzene 
• 140134-65-2 (E)-3-<4-(methylthio)phenyl>propenoic acid 

Downstream Products

• 718610-52-7 (E)-(4S,5R)-1-(3-[4-methanesulfonylphenyl]acryloyl)-3,4-dimethyl-5-phenyl-imidazolidin-2-one 
• 718636-32-9 (S) N-(3-phenyl-3-[4-methanesulphonylphenyl]propyl)-4-(3-phenylpropyl)piperidine 
• 718637-41-3 (S) N-(4-methanesulphonylphenyl)-1-[3-phenyl-3-(4-methanesulphonylphenyl)-propyl]piperidin-4-yl acetamide 
• 527744-20-3 (S) 3-phenyl-3-(4-methanesulphonylphenyl)propionaldehyde 
• 1391625-75-4 (3S,6S)-3,6-diisobutyl-4-((E)-3-(4-(methylsulfonyl)phenyl)acryloyl)piperazin-2-one 
• 1373543-40-8 ethyl (2R,3S)-3-hydroxy-3-[4-(methylsulfonyl)phenyl]-2-{[(4-nitrophenyl)sulfonyl]oxy}propanoate 
• 1373543-39-5 methyl (2R,3S)-2,3-dihydroxy-3-[4-(methylsulfonyl)phenyl]propanoate 
• 1373543-38-4 ethyl (2R,3S)-2,3-dihydroxy-3-[4-(methylsulfonyl)phenyl]propanoate 
• 137473-27-9 ethyl (2E)-3-[4-(methylsulfonyl)phenyl]acrylate 
• 186457-49-8 methyl (2E)-3-[4-(methylsulfonyl)phenyl]acrylate 
• 157142-64-8 (3S,4R)-2-(dichloromethyl)-4,5-dihydro-α-[4-(methylsulfonyl)phenyl]oxazole-4-methanol 
• 126813-11-4 D-threo-2-(dichloromethyl)-5-(4-methanesulfonylphenyl)-4,5-dihydro-1,3-oxazol-4-yl methanol 
• 143026-79-3 (4S,5R)-2-(dichloromethyl)-4-(fluoromethyl)-5-(4-(methylsulfonyl)phenyl)-4,5-dihydrooxazole 
• 73231-34-2 Florfenicol 

Relevant articles and documents

Hydroxamic acids block replication of hepatitis c virus

Intrigued by the role of protein acetylation in hepatitis C virus (HCV) replication, we tested known histone deacetylase (HDAC) inhibitors and a focused library of structurally simple hydroxamic acids for inhibition of a HCV subgenomic replicon. While known HDAC inhibitors with varied inhibitory profiles proved to be either relatively toxic or ineffective, structure-activity relationship (SAR) studies on cinnamic hydroxamic acid and benzo[b]thiophen-2-hydroxamic acid gave rise to compounds 22 and 53, which showed potent and selective anti-HCV activity and therefore are promising starting points for further structural optimization and mechanistic studies.

Syntheses, crystal structures, and antimicrobial activities of nickel(II) and cadmium(II) complexes with 4-methylsulfonyl cinnamate and diamines

Two metal complexes, [NiII(mscinn)2(pda)2] (1) and [CdII(mscinn)2(dmeda)2·2H 2O] (2) (mscinn=4-methylsulfonyl cinnamate, pda=propane-1,3-diamine, dmeda=N′, N′-dimethylethane-1,2-diamine), were synthesized by reacting 4-methylsulfonyl cinnamate with the diamines and metal salts. Their structures were determined by single-crystal X-ray diffraction analysis. Crystal parameters of 1: C26H38N4NiO8S 2, M=657.43, monoclinic, P21/c, a=16.6123(8) A, b=8.5956(4) A, c=11.2047(5) A, β=107.423(1)°, V=1526.54(12) A3, Z=2, Dcalcd=1.430 g cm-3, F(000)=692, μ=0.825mm-1, R1=0.0257, wR 2=0.0669. Crystal data of 2: C28H42CdN 4O8S2 · 2(H2O), M=775.24, monoclinic, P21/c, a=9.8278(4) A, b=11.6611(5) A, c=15.3972(7) A, β=96.195(1)°, V=1754.26(13) A3, Z=2, Dcalcd=1.468 g cm-3, F(000)=804, μ=0.798mm -1, R1=0.0299, wR2=0.0770. Antimicrobial activities for 1 and 2 against Escherichia coli, Pseudomonas putida, Bacillus subtilis, and Bacillus cereus had better antibacterial activity than their parent carboxylic acid against Gram-positive bacteria (B. subtilis and B. cereus). The cadmium complex of the cinnamate displayed high inhibitory activity with an MIC value of 5 μgmL-1 against P. putida, while the nickel complex also exhibited good inhibitory potency with an MIC value of 5 μgmL-1 against B. subtilis.

NEW BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS

This invention relates to compounds, which are generally anti-inflammatory and analgesic compounds, and which are represented by Formula I: wherein A is a —CH2—, —C(O)—, —O—, —S—, —S(O)—, or —S(0)2— and the other substituents are as defined in the specification; or prodrugs, individual isomers, mixtures of isomers, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.